Flex Pharma, Inc. (FLKS) financial statements (2021 and earlier)

Company profile

Business Address 2450 HOLCOMBE BLVD
HOUSTON, TX 77021
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1141033619134
Cash and cash equivalents1141019226734
Short-term investments   143925 
Restricted cash and investments  0    
Receivables4 000  
Inventory, net of allowances, customer advances and progress billings  000  
Inventory  000  
Prepaid expense11     
Deferred costs      1
Other current assets00     
Other undisclosed current assets 00111(1)
Total current assets:1651035629234
Noncurrent Assets
Property, plant and equipment0000100
Long-term investments and receivables     2 
Long-term investments     2 
Intangible assets, net (including goodwill)99     
Goodwill99     
Restricted cash and investments   0000
Deferred costs      1
Other noncurrent assets00  0 0
Other undisclosed noncurrent assets      0
Total noncurrent assets:9900131
TOTAL ASSETS:25141035639536
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2213331
Accounts payable2202111
Accrued liabilities  00000
Employee-related liabilities  01110
Deferred revenue 1
Debt01     
Derivative instruments and hedges, liabilities00     
Restructuring reserve  0    
Deferred revenue and credits0000
Deferred tax liabilities    0
Other undisclosed current liabilities  03100
Total current liabilities:2316431
Noncurrent Liabilities
Liabilities, other than long-term debt   0000
Deferred revenue and credits0000
Other liabilities     00
Total noncurrent liabilities:   0000
Other undisclosed liabilities00     
Total liabilities:3316431
Stockholders' equity
Stockholders' equity attributable to parent22119295992(7)
Common stock0000000
Additional paid in capital42231421401361291
Accumulated other comprehensive loss   (0)(0)(0) 
Accumulated deficit(19)(12)(133)(111)(77)(37)(8)
Other undisclosed stockholders' equity      41
Total stockholders' equity:2211929599234
TOTAL LIABILITIES AND EQUITY:25141035639536

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues531110 
Revenue, net11  
Net investment income  0 00 
Cost of revenue
(Cost of Goods and Services Sold)
  (0)(0)(0)  
Gross profit:530110 
Operating expenses(13)(12)(23)(36)(41)(29) 
Other undisclosed operating income  000  
Operating loss:(8)(8)(22)(35)(40)(29) 
Nonoperating income (expense)0    (0) 
Investment income, nonoperating     (0) 
Other nonoperating income0      
Loss from continuing operations before equity method investments, income taxes:(8)(8)(22)(35)(40)(29) 
Other undisclosed loss from continuing operations before income taxes     (0) 
Net loss:(8)(8)(22)(35)(40)(29) 
Other undisclosed net income attributable to parent010000 
Net loss attributable to parent:(7)(7)(22)(34)(39)(29) 
Preferred stock dividends and other adjustments(0)      
Net loss available to common stockholders, diluted:(8)(7)(22)(34)(39)(29) 

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(8)(8)(22)(35)(40)(29) 
Other comprehensive income (loss)    0(0) 
Comprehensive loss:(8)(8)(22)(35)(40)(29) 
Other undisclosed comprehensive income, net of tax, attributable to parent  0000 
Comprehensive loss, net of tax, attributable to parent:(8)(8)(22)(34)(39)(29) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: